Source/Disclosures
Published by:
Disclosures:
White reports support from Gilead Sciences to assist with HIV screening and prevention services. See the study for the other authors’ relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . ” data-action=”subscribe”> Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Back to Healio
Key takeaways:
- A hospital in California offered patients who tested positive for HIV in the emergency department 14 days of ART.
- Patients who received the “starter packs” were less likely to be lost to follow-up.
A hospital in California offered patients who tested positive for HIV in the emergency department an initial 14-day supply of ART, believing it would minimize treatment barriers and encourage them to seek outside care.
The program showed promise. According to findings published in Open Forum Infectious Diseases, almost 90% of patients who were offered a “starter pack” of HIV treatment in the ED accepted it and more than 80% of them followed up at a clinic.
A rapid ART kit in emergency departments could help doctors steer people newly diagnosed with HIV toward treatment more quickly. Image: Adobe Stock
“Our program is unique in that emergency physicians provided rapid ART for patients with a preliminary new HIV diagnosis … as well as those with a previous HIV diagnosis who were treatment naive,” Douglas AE White, MD, and colleagues at Alameda Health System in Oakland, California, wrote.
“The protocol was developed with strict exclusion criteria by using an embedded electronic health record checklist to maximize the safety of emergency physician-administered ART: a design that aimed to facilitate availability 24 hours a day without reliance on specialty consultation,” they wrote.
Most patients who tested positive were ineligible for the rapid ART packs, according to the protocol, including a large proportion of patients who were ineligible because of previous ART use, which increases the risk for ART resistance. White and colleagues referred these patients to an HIV specialist first.
During the 1-year study period, 10,606 HIV tests were performed at Alameda, with 106 coming back positive. Of these, 31 patients were eligible for rapid ART, 26 were offered it, and 25 accepted for an overall 23.6% ED rapid ART treatment rate. Two patients who received ED rapid ART were later confirmed to be HIV negative.
White and colleagues said they settled on 14 days of treatment because they thought it would be enough to “bridge the gap” between the ED visit and an initial appointment. They polled HIV physicians to determine which ART medication to offer, ultimately settling on once-a-day bictegravir/emtricitabine/tenofovir alafenamide.
According to White and colleagues, patients who were provided rapid ART in the ED were more likely to follow up within 30 days than those who were not (82.6% vs. 50%).
The researchers noted that more than half of patients assessed for ED rapid ART had previously been diagnosed with HIV and nearly 90% reported previous ART use. Although the researchers said this may represent a missed opportunity for reengaging these patients in care, additional testing and treatment may be necessary, which is why they did not receive rapid ART.
The protocol, entirely overseen and executed by emergency physicians once implemented, has the potential to increase early HIV treatment, the authors wrote.
“We show that it is feasible for emergency physicians to follow an institution-specific protocol, with guidance from a peer colleague and navigators, to integrate rapid ART delivery into an ED that supports HIV screening,” White and colleagues wrote in the study.
perspective
back to top
Paul A Volberding, MD
The optimum time to initiate ART following diagnosis has been the subject of long debate. In the early era of HIV treatment, drugs were often of limited potency, occasioned frequent side effects and were inconvenient. Those facts led many to propose delaying until serious immune compromise had occurred.
As drugs improved, and clinical trials proved that treatment at all disease stages was beneficial, early initiation was considered appropriate but many still recommended that some delay was useful to establish strong linkages to primary medical care. More recently, clinical experience has shown that essentially immediate ART initiation is beneficial, allowing rapid immune reconstitution and avoiding the loss of care in those whom treatment is delayed, leading in many cases to later reappearance with advanced disease and potentially further HIV transmission.
The article by White and colleagues takes an immediate treatment approach even further, treating those diagnosed in emergency care units by providing “rapid ART packs,” along with referral to primary care programs. This work comes from a group long interested in HIV diagnosis in ED settings and is to be applauded. The more HIV treatment is facilitated by reducing care barriers, the closer we might come to truly ending the HIV epidemic.
Paul A Volberding, MD
Chief Medical Editor, Infectious Disease News
Professor emeritus of medicine
University of California, San Francisco
Disclosures: Volberding reports no relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . ” data-action=”subscribe”> Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Back to Healio
